OxyContin formula change has many abusers switching to heroin
A new formulation of OxyContin makes inhaling or injecting the drug more difficult, so drug abusers are turning instead to heroin (pictured above). Credit: US Drug Enforcement Administration
A change in the formula of the frequently abused prescription painkiller OxyContin has many abusers switching to a drug that is potentially more dangerous, according to researchers at Washington University School of Medicine in St. Louis.
The formula change makes inhaling or injecting the opioid drug more difficult, so many users are switching to heroin, the scientists report in the July 12 issue of the New England Journal of Medicine.
For nearly three years, the investigators have been collecting information from patients entering treatment for drug abuse. More than 2,500 patients from 150 treatment centers in 39 states have answered survey questions about their drug use with a particular focus on the reformulation of OxyContin.
The widely prescribed pain-killing drug originally was thought to be part of the solution to the abuse of opioid drugs because OxyContin was designed to be released into the system slowly, thus not contributing to an immediate "high." But drug abusers could evade the slow-release mechanism by crushing the pills and inhaling the powder, or by dissolving the pills in water and injecting the solution, getting an immediate rush as large amounts of oxycodone entered the system all at once.
In addition, because OxyContin was designed to be a slow-release form of the generic oxycodone, the pills contained large amounts of the drug, making it even more attractive to abusers. Standard oxycodone tablets contained smaller amounts of the drug and did not produce as big a rush when inhaled or injected.
Then in 2010, a new formulation of the drug was introduced. The new pills were much more difficult to crush and dissolved more slowly. The idea, according to principal investigator Theodore J. Cicero, PhD, was to make the drug less attractive to illicit users who wanted to experience an immediate high.
This video is not supported by your browser at this time.
A change in the formula of a frequently abused prescription painkiller seems to have convinced many drug abusers to switch to a substance that’s potentially more dangerous. Washington university researchers have found that former OxyContin abusers are apparently switching to heroin. Jim Dryden reports… Credit: Washington University BioMed Radio
"Our data show that OxyContin use by inhalation or intravenous administration has dropped significantly since that abuse-deterrent formulation came onto the market," says Cicero, a professor of neuropharmacology in psychiatry. "In that sense, the new formulation was very successful."
The researchers still are analyzing data, but Cicero says they wanted to make their findings public as quickly as possible. The new report appears as a letter to the editor in the journal. Although he found that many users stopped using OxyContin, they didn't stop using drugs.
"The most unexpected, and probably detrimental, effect of the abuse-deterrent formulation was that it contributed to a huge surge in the use of heroin, which is like OxyContin in that it also is inhaled or injected," he says. "We're now seeing reports from across the country of large quantities of heroin appearing in suburbs and rural areas. Unable to use OxyContin easily, which was a very popular drug in suburban and rural areas, drug abusers who prefer snorting or IV drug administration now have shifted either to more potent opioids, if they can find them, or to heroin."
Since the researchers started gathering data from patients admitted to drug treatment centers, the number of users who selected OxyContin as their primary drug of abuse has decreased from 35.6 percent of respondents before the release of the abuse-deterrent formulation to 12.8 percent now.
When users answered a question about which opioid they used to get high "in the past 30 days at least once," OxyContin fell from 47.4 percent of respondents to 30 percent. During the same time period, reported use of heroin nearly doubled.
In addition to answering a confidential questionnaire when admitted to a drug treatment program, more than 125 of the study subjects also agreed to longer phone interviews during which they discussed their drug use and the impact of the new OxyContin formulation on their individual choices.
"When we asked if they had stopped using OxyContin, the normal response was 'yes,'" Cicero says. "And then when we asked about what drug they were using now, most said something like: 'Because of the decreased availability of OxyContin, I switched to heroin.'"
These findings may explain why so many law enforcement officials around the country are reporting increases in heroin use, Cicero says. He compares attempts to limit illicit drug use to a levee holding back floodwaters. Where the new formulation of OxyContin may have made it harder for abusers to use that particular drug, the "water" of illicit drug use simply has sought out other weak spots in the "levee" of drug policy.
"This trend toward increases in heroin use is important enough that we want to get the word out to physicians, regulatory officials and the public, so they can be aware of what's happening," he says. "Heroin is a very dangerous drug, and dealers always 'cut' the drug with something, with the result that some users will overdose. As users switch to heroin, overdoses may become more common."
More information: Cicero TJ, Ellis MS, Surrat HL. Effect of abuse-deterrent formulation of OxyContin. The New England Journal of Medicine, July 12, 2012.
Journal reference:
New England Journal of Medicine
Provided by
Washington University School of Medicine
-
FDA: 'limited' benefit with tamper-proof OxyContin
Sep 22, 2009 |
not rated yet |
0
-
Illicit Canadian opioid use exceeds heroin
Nov 21, 2006 |
not rated yet |
0
-
Abuse of painkillers can predispose adolescents to lifelong addiction
Sep 10, 2008 |
not rated yet |
0
-
Study focuses on prescription addiction
Apr 23, 2007 |
not rated yet |
0
-
Pfizer will buy King Pharmaceuticals for $3.6B
Oct 12, 2010 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
-
Marie Curie's leukemia
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
Breakup of physician, drug company relationship could improve health care, cut cost
A new report suggests that improved health care and significant reductions in drug costs might be attained by breaking up the age-old relationship between physicians and drug company representatives who promote the newest, ...
Medications
18 hours ago |
5 / 5 (1) |
0
FDA has safety concerns on Merck insomnia drug
Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.
Medications
19 hours ago |
not rated yet |
0
US adviser on board of firm that sold anthrax drug
(AP)—Former Navy Secretary Richard J. Danzig, who has served as a bio-warfare adviser to the president, the Pentagon, and the Department of Homeland Security, urged the government to stockpile an anti-anthrax drug while ...
Medications
May 20, 2013 |
5 / 5 (1) |
0
Acne pill benefits outweigh blood clot risk: EU agency
Europe's medicines watchdog said Friday the benefits of acne drug Diane-35, also widely used as a contraceptive, outweigh the risk of developing blood clots in the veins—when correctly prescribed.
Medications
May 17, 2013 |
not rated yet |
0
First influenza vaccine brought to clinical testing
Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their ...
Medications
May 17, 2013 |
5 / 5 (1) |
1
Biomarker trio predicts near-term heart risk
(Medical Xpress)—Cardiologists have identified a trio of biomarkers that may predict which patients with heart disease have a high risk of heart attack or death in the next two years.
Holding drivers' attention
Each day, an average of nine people are killed in the United States and more than 1,000 injured by drivers doing something other than driving.
New theory offers clues to vital 'repair and maintenance' role of sleep
(Medical Xpress)—We spend about a third of our life asleep, but why we need to do so remains a mystery. In a recent publication, researchers at University of Surrey and University College London suggest a new hypothesis, ...
Salt consumption in India: The need for data to initiate population-based prevention efforts
(Medical Xpress)—International researchers are studying the salt intake of Indian adults to provide vital new data to aid the development of a national salt reduction strategy.
Eyes on the sun: Child sunshine exposure and eye development
(Medical Xpress)—Exposure to sunshine as a small child is crucial to the development of a healthy eye according to results of long-term myopia study conducted by University of Sydney researchers.
Genetic predictors of postpartum depression uncovered
Johns Hopkins researchers say they have discovered specific chemical alterations in two genes that, when present during pregnancy, reliably predict whether a woman will develop postpartum depression.